TCRG Cannaisseur Group Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1879270 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY78.2%
TTM EPS YoY100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-162,372.1%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets2,151,675.0%
Debt / equity—
Current ratio0.00x
Interest coverage-403.02x
Cash quality & payout
Operating cash flow / net income0.28x
Accruals ratio-116,771.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0 | $700 | $53,130 | $88,145 |
| Cost of revenue | $910 | $4,275 | $26,976 | $42,839 |
| Gross profit | -$910 | -$3,575 | $26,154 | $45,306 |
| SG&A expense | $1.72M | $1.26M | $216,054 | $137,207 |
| Operating income | -$1.72M | -$1.27M | -$189,900 | -$91,901 |
| Interest expense | $4,277 | $6,427 | $1,654 | $2,112 |
| Pretax income | -$1.81M | -$1.27M | -$172,586 | -$94,013 |
| Income tax | $0 | $0 | $0 | $0 |
| Net income | -$1.77M | -$1.27M | -$128,025 | -$80,147 |
| EBITDA | — | -$1.27M | -$186,078 | -$87,643 |
| EPS (basic) | -0.03 | -0.03 | 0.00 | 0.00 |
| EPS (diluted) | -0.03 | -0.03 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 53.90M | 43.81M | 39.70M | 36.17M |
| Balance sheet | ||||
| Cash & equivalents | $22 | $563 | $38,390 | $18,534 |
| Receivables | $0 | $285 | $0 | $807 |
| Inventory | $118 | $1,028 | $5,303 | $13,456 |
| Current assets | $140 | $1,876 | $43,693 | $35,797 |
| PP&E, net | — | — | $0 | $3,822 |
| Total assets | $140 | $1,876 | $43,693 | $59,289 |
| Current liabilities | $210,632 | $229,113 | $70,904 | $55,934 |
| Short-term debt | — | — | $6,377 | $1,517 |
| Long-term debt | — | — | $65,783 | $25,783 |
| Total debt | — | — | $72,160 | $27,300 |
| Total liabilities | $235,431 | $305,576 | $136,687 | $81,717 |
| Shareholders' equity | -$92,889 | -$233,639 | -$26,501 | -$496 |
| Net debt | — | — | $33,770 | $8,766 |
| Shares outstanding | 60.46M | 44.34M | 42.55M | 37.20M |
| Cash flow statement | ||||
| Operating cash flow | -$127,451 | -$110,627 | -$126,074 | -$23,935 |
| Financing cash flow | $126,910 | $72,800 | $145,930 | $36,445 |
| Depreciation & amortization | — | $0 | $3,822 | $4,258 |
| Stock-based compensation | $1.29M | $1.04M | $0 | — |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.